Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
6/5/18: Each of the company’s current investors participated in the financing, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, and Schrödinger. Bruce Booth, Partner of Atlas Venture, Board Chair and co-founder of Nimbus noted, “this round of investment reflects the existing syndicate’s strong and enthusiastic support for Nimbus’ proven management team and exciting new programs.”
Ancora Heart Announces $17.8 Million Financing for First-of-Its-Kind Therapy for Systolic Heart Failure
5/30/18: “Effectively treating heart failure and FMR is incredibly challenging today, and there are enormous unmet needs for these patients. This funding represents an important milestone that will advance the AccuCinch system as an alternative option that addresses the shortcomings of current heart failure and FMR treatments,” said Jeff Closs, president and CEO of Ancora Heart.
The Vesalius unique concept marries surgery and cardiology to deliver a percutaneous treatment for mitral valve prolapse (also known as degenerative mitral regurgitation), a serious and very common heart valve disease.
Vesper Medical Completes $10.5 M Series A Financing to Drive Development of Next Generation Venous Stents
5/11/18: “We are enthusiastic to partner with the Vesper team in their mission to provide a best-in-class solution to treat deep venous disease. Venous intervention has been long underserved as a place for innovation, but is now at a growth inflection point as the next major category in the peripheral vascular market,” said Justin Klein, MD, JD
Cardiac Dimensions Announces $39 Million Series B Financing for Innovative Device to Treat Patients With Heart Failure
The funds will be used for clinical studies and commercial expansion in the European Union and Australia.
4/19/18: Combination of $3 million in equity financing and conversion of $7 million in convertible notes will fund clinical trial for the Emboliner™ Embolic Protection Catheter.
Tmunity Therapeutics, Inc., a private, clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced an additional $35 million Series A investment from Kleiner Perkins and...
Intact Vascular Announces $20 Million Series C Financing to Fund Company through PMA Approval of the Tack Endovascular System®
“We continue to be impressed with the extensive clinical program that Intact Vascular is advancing to illustrate the significant clinical benefits that a better solution for dissections can have on angioplasty for peripheral arterial disease and critical limb ischemia,” said Justin Klein, MD, JD, Partner at New Enterprise Associates and member of the Intact Vascular Board of Directors.